


Claims 22 and 24-30 were rejected under 35 U.S.C. §112(1). The claims have been amended to the claim scope which the office action states is an enabling claim scope. Hence the rejection should be withdrawn.

Claims 22 and 24-30 were rejected under 35 U.S.C. §112(2). The claims have been amended to overcome the rejection. Hence the rejection should be withdrawn. Support for the amendment "by lowering the level of a gonadotrophin secretion" can be found at at least page 24, lines 25-29 of the specification.

Claims 29-30 are hereby cancelled without prejudice to further prosecution at a later date.

All issues raised by the Office Action have been addressed. Reexamination, reconsideration and allowance of claims 22 and 24-28 is requested.

Respectfully submitted,


Stephen Donovan
Registration Number 33,433


Date February 18, 2004

Stephen Donovan
Allergan, Inc., Legal Department
2525 Dupont Drive
Irvine, CA 92612
Telephone: 714 246 4026
Fax: 714 246 4249

CERTIFICATE OF EXPRESS MAIL UNDER 37 C.F.R. § 1.10

I hereby certify that this Response to Office Action and the documents referred to as enclosed therein are being deposited with the United States Postal Service on this date **February 18, 2004** in an envelope as "Express Mail Post Office to Addressee" Mailing Label number **EV193721181US** addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Bartholomew
Name of person mailing paper
Date: February 18, 2004


Signature of person signing